2 weeks Ago By ABMN Staff
Dr. Reddy’s Laboratories ( NYSE:RDY – Get Free Report ) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Wednesday.
Separately, Barclays dropped their price objective on shares of Dr. Reddy’s Laboratories from $17.40 to $17.
00 and set an “overweight” rating for the company in a report on Wednesday, November 6th. Get Our Latest Analysis on Dr. Reddy’s Laboratories Dr.
Reddy’s Laboratories Trading Down 2.2 % Institutional Inflows and Outflows Large investors have recently bought and sold shares of the stock. Jane Street Group LLC lifted its position in shares of Dr.
Reddy’s Laboratories by 2,197.8% during the first quarter. Jane Street Group LLC now owns 113,168 shares of the company’s stock worth $8,301,000 after purchasing an additional 108,243 shares in the last quarter.
OLD Mission Capital LLC lifted its position in shares of Dr. Reddy’s Laboratories by 66.2% during the first quarter.
OLD Mission Capital LLC now owns 47,537 shares of the company’s stock worth $3,487,000 after purchasing an additional 18,930 shares in the last quarter. O Shaughnessy Asset Management LLC lifted its position in shares of Dr. Reddy’s Laboratories by 11.
3% during the first quarter. O Shaughnessy Asset Management LLC now owns 62,177 shares of the company’s stock worth $4,561,000 after purchasing an additional 6,322 shares in the last quarter. Frank Rimerman Advisors LLC acquired a new stake in Dr.
Reddy’s Laboratories in the second quarter valued at approximately $2,633,000. Finally, Artemis Investment Management LLP raised its holdings in Dr. Reddy’s Laboratories by 92.
6% in the second quarter. Artemis Investment Management LLP now owns 15,600 shares of the company’s stock valued at $1,189,000 after acquiring an additional 7,500 shares in the last quarter. Institutional investors and hedge funds own 14.
02% of the company’s stock. Dr. Reddy’s Laboratories Company Profile ( Get Free Report ) Dr.
Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Read More Receive News & Ratings for Dr. Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories and related companies with MarketBeat.
com's FREE daily email newsletter ..
